Garner v. Medicis Pharmaceutical Corporation

CourtDistrict Court, D. Arizona
DecidedSeptember 27, 2023
Docket2:21-cv-00145
StatusUnknown

This text of Garner v. Medicis Pharmaceutical Corporation (Garner v. Medicis Pharmaceutical Corporation) is published on Counsel Stack Legal Research, covering District Court, D. Arizona primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Garner v. Medicis Pharmaceutical Corporation, (D. Ariz. 2023).

Opinion

1 WO 2 3 4 5 6 IN THE UNITED STATES DISTRICT COURT 7 FOR THE DISTRICT OF ARIZONA

9 Alec Garner, et al., No. CV-21-00145-PHX-GMS

10 Plaintiffs, ORDER

11 v.

12 Medicis Pharmaceutical Corporation, et al.,

13 Defendants. 14 15 16 Pending before the Court is Medicis Pharmaceutical Corporation and Bausch Health 17 US, LLC’s (“Defendants”) Motion for Summary Judgment (Doc. 55). For the following 18 reasons, the motion is denied. 19 BACKGROUND 20 Plaintiffs bring their case under the Arizona Consumer Fraud Act (“ACFA”), A.R.S. 21 § 44-1522. The four individual plaintiffs in this case each allege to have suffered adverse 22 conditions resulting from their prescribed use of Solodyn. (Doc. 14 at 8–14). Solodyn is 23 an acne-treatment drug. (Doc. 14 at 3). Plaintiffs’ case focuses on certain language in 24 Defendants’ promotional materials: “The safety of using Solodyn beyond 12 weeks has not 25 been studied and is not known.” (“12-Week Language”) (Doc. 13 at 4–5). The 26 promotional language differed from the language the Food and Drug Administration 27 approved and required in 2006: “Safety of Solodyn has not been established beyond 12 28 weeks of use.” (Doc. 14 at 3). 1 Plaintiffs allege that by February 2008, Medicis, and later Bausch, studied the safety 2 of using Solodyn beyond 12 weeks and discovered elevated liver function tests in one 3 percent of patients after 25 weeks and drug-induced lupus in over half a percent of patients. 4 (Doc. 14 at 4–5). Yet, according to Plaintiffs, Defendants continued using the 12-Week 5 Language. Plaintiffs identify Defendants’ use of the 12-Week Language on carriers 6 physically attached to MediSAVE cards—promotional cards providing holders a discount 7 on prescription drugs. (Doc. 67-3 at 3). At oral argument, Plaintiffs admitted that proper 8 language was included in other publications released by Defendants. Each Plaintiff took 9 prescribed Solodyn and each was eventually diagnosed with drug-induced hepatitis, lupus, 10 or elevated liver enzymes. (Doc. 14 at 9, 11–13). 11 On December 28, 2020, Plaintiffs filed suit against Defendants in Maricopa County 12 Superior Court for violation of the ACFA. (Doc. 1–3, Ex. A). Defendants removed the 13 case to this Court on January 27, 2021. (Doc. 1). On October 14, 2022, Defendants filed 14 a Motion for Summary Judgment asserting Plaintiffs have failed to show reliance on the 15 12-week language. (Doc. 55 at 2–3). Defendants further allege Plaintiffs’ claims are time 16 barred under the ACFA’s one-year statute of limitations. 17 DISCUSSION 18 I. Legal Standard 19 Summary judgment is proper when the movant “shows that there is no genuine 20 dispute as to any material fact and the movant is entitled to judgment as a matter of law.” 21 Fed. R. Civ. P. 56(a). The Court views the evidence “in a light most favorable to a non- 22 moving party.” Warren v. City of Carlsbad, 58 F.3d 439, 441 (9th Cir. 1995). Substantive 23 law determines which facts are material, and “[o]nly disputes over facts that might affect 24 the outcome of the suit under the governing law will properly preclude the entry of 25 summary judgment.” Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 248 (1986). “A fact 26 issue is genuine ‘if the evidence is such that a reasonable jury could return a verdict for the 27 [non-moving] party.’” Villiarimo v. Aloha Island Air, Inc., 281 F.3d 1054, 1061 (9th Cir. 28 2002) (quoting Anderson, 477 U.S. at 248). Thus, the non-moving party must show that 1 the genuine factual issues “can be resolved only by a finder of fact because they may 2 reasonably be resolved in favor of either party.” Anderson, 477 U.S. at 250. 3 II. Analysis 4 In their Motion for Summary Judgment, Defendants assert Plaintiffs cannot show 5 any reliance on the alleged 12-Week Language misrepresentation. Additionally, they 6 assert that Defendants’ claims are time barred. 7 A. Reliance 8 The ACFA requires Plaintiffs to show “(1) a false promise or misrepresentation 9 made in connection with the sale or advertisement of ‘merchandise,’ and (2) consequent 10 and proximate injury resulting from the misrepresentation.” Watts v. Medicis Pharm. 11 Corp., 239 Ariz. 19, 28, 365 P.3d 944, 953 (Ariz. 2016) (citing Kuehn v. Stanley, 208 Ariz. 12 124, 129, ¶ 16, 91 P.3d 346, 351, ¶ 16 (Ariz. Ct. App. 2004)). A material omission can 13 support an ACFA claim. A.R.S. § 44–1522(A). Plaintiffs must show reliance to succeed 14 on an ACFA claim. Kuehn, 208 Ariz. at 129, ¶ 16, 91 P.3d at 351, ¶ 16. While reliance 15 on a material omission is necessary, it need not be reasonable. See Schellenbach v. 16 GoDaddy.com., 321 F.R.D. 613, 624 (D. Ariz. 2017). Reliance, however, must be possible. 17 See Kuehn, 208 Ariz. at 130, ¶ 20, 91 P.3d at 352, ¶ 20 (holding reliance was not possible 18 because the alleged false report was received only after the Plaintiffs entered the contract). 19 In other words, to fulfill the reliance element under the ACFA at summary judgement, a 20 plaintiff must be able to present facts showing reliance was actually possible at the time of 21 the fraudulent misrepresentation. 22 Defendants have not shown an absence of a genuine dispute of material fact on the 23 issue of reliance. Determining the facts on this issue requires weighing the credibility of 24 Plaintiffs’ and witness testimony. The Court does not weigh evidence or credibility during 25 summary judgment, leaving this issue for the jury. Anderson, 477 U. S. at 255. Each 26 Plaintiff has alleged sufficient facts to survive Defendants’ Summary Judgment. This is 27 because determining the accuracy and credibility of Plaintiffs’ sworn testimony is a matter 28 for a jury to weigh. 1 1. Alec Garner 2 Under oath, Plaintiff Alec Garner testified that he remembered receiving the 3 MediSAVE card and whatever information was included with it. (Doc. 67-4 at 2). 4 Furthermore, Mr. Garner testified that he believed the MediSAVE card came with a “one- 5 sheeter.” (Doc. 67-4 at 3–6). Further, Mr. Garner’s mother testified that she would have 6 reviewed and relied on any information provided to her. (Doc. 67-5 at 6). The question of 7 whether this testimony is sufficient to show receipt and reliance on the 12-Week Language 8 is a question of fact for a jury to determine. 9 2. Erica Lupori 10 Under oath, Plaintiff Erica Lupori testified that she received a brochure along with 11 her MediSAVE card. (Doc. 67-6 at 2). She does not recall the exact look of the brochure, 12 but remembers it being “attractive.” (Doc. 67-6 at 2). She remembers reading the brochure 13 and learning about increased risk of headaches and sunburns. (Doc. 67-6 at 4-5). These 14 are both warnings included with the carrier that MediSAVE cards are attached to. (Doc. 15 67-3 at 3). Further, Ms. Lupori testified that she recalled receiving the card and had read 16 a pamphlet included with the card. (Doc. 67-6 at 6). Finally, Ms. Lupori testified that 17 relied on all the information in the brochure and/or pamphlet. (Doc. 67-6 at 8). Like Mr. 18 Garner’s claim, whether Ms. Lupori’s testimony is sufficient to prove her claim is a 19 question of fact for a jury to determine. 20 3.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Alaface v. National Investment Co.
892 P.2d 1375 (Court of Appeals of Arizona, 1994)
Kuehn v. Stanley
91 P.3d 346 (Court of Appeals of Arizona, 2004)
Grammatico v. Industrial Commission
90 P.3d 211 (Court of Appeals of Arizona, 2004)
Amanda Watts v. Medicis Pharmaceutical Corporation
365 P.3d 944 (Arizona Supreme Court, 2016)
Schellenbach v. GoDaddy.com, LLC
321 F.R.D. 613 (D. Arizona, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
Garner v. Medicis Pharmaceutical Corporation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/garner-v-medicis-pharmaceutical-corporation-azd-2023.